A clinical trial update dated November 10, 2026 confirms that a study involving leuprolide, a gonadotropin-releasing hormone agonist, is currently recruiting participants. The trial, registered as NCT05567198, is titled "Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires." It focuses on subjects with systemic lupus erythematosus (SLE) who are receiving cyclophosphamide treatment. The study's phase is not specified in the available record. No trial phase designation was listed, and no results have been posted at this time. The trial status remains listed as recruiting, meaning the study is actively seeking eligible participants. This update reflects only the current recruitment status and does not indicate any findings, outcomes, or conclusions about leuprolide's effects on ovarian preservation. No efficacy or safety data from this trial have been reported as of this date. Readers interested in the study can review the official listing for further details on eligibility criteria and trial design. For more background on leuprolide as a compound, readers can consult the compound overview.
Leuprolide Trial Update: Ovarian Preservation Study in SLE Still Recruiting
See the full leuprolide overview
Source: https://clinicaltrials.gov/study/NCT05567198